DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating ...
DexCom presented outlook on diabetes market at the ADA Conference, highlighting potential for growth with new products like Stelo and DexCom ONE. DexCom's strategy differs from Abbott Labs, focusing ...
2don MSN
Barclays downgrades Dexcom (DXCM) to underweight citing intensifying competition in core segments
DexCom Inc. (NASDAQ:DXCM) is one of the best US stocks to buy and hold in 2026. On January 12, Barclays downgraded DexCom to Underweight from Equal Weight with a price target of $71, which was brought ...
Add Yahoo as a preferred source to see more of our stories on Google. (COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in ...
DexCom is expected to remain an outperformer in the healthcare sector in 2024, driven by M&A activity and the growth of GLP-1 weight loss drugs. The company's continuous glucose monitoring ("CGM") ...
The medical device specialist lagged the market, and even with a bit of a rebound toward the second half of 2025, shares are ...
DexCom's DXCM shares have risen 6.9% since Tuesday last week, while yesterday’s after-market movement took the rally to nearly 8%. Last week, the company presented a positive picture for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results